CriticalAntiepileptics. Barbiturates×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Rivaroxaban is a substrate of the CYP3A4/5 and CYP2J2 enzymes and of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (rivaroxaban label, US Food and Drug Administration, FDA). According to its own SmPC, phenobarbital induces cytochrome P450 enzymes, glucuronosyltransferases and P-gp, and it may speed up the metabolism and elimination of many drugs and reduce their efficacy (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The EU rivaroxaban SmPC lists phenobarbital among the strong CYP3A4 inducers that may lower rivaroxaban plasma levels (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). No figures are given for phenobarbital. With rifampicin, the rivaroxaban area under the concentration–time curve (AUC) fell by about 50%, with a parallel loss of effect (rivaroxaban SmPC, EMA).
Symptoms
The main risk is thrombosis because rivaroxaban works less well: phenobarbital reduces the efficacy of oral anticoagulants (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation, this means stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking.
Management
The combination is contraindicated in the practical guide of the European Heart Rhythm Association (EHRA): its antiepileptic drug table marks the rivaroxaban and phenobarbital cell as contraindicated because of reduced anticoagulant levels (EHRA 2021). The EU rivaroxaban SmPC says to avoid combining rivaroxaban with strong CYP3A4 inducers, phenobarbital included, unless the patient is closely monitored for signs and symptoms of thrombosis (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label says to avoid rivaroxaban with drugs that are combined P-glycoprotein (P-gp) and strong CYP3A inducers. Phenobarbital is not among its examples (rivaroxaban label, US Food and Drug Administration, FDA). The phenobarbital SmPC lists oral anticoagulants among the combinations that need caution, clinical monitoring or dose adjustment during phenobarbital treatment and after it stops. Adjust the anticoagulant dose throughout phenobarbital treatment and for 8 days after stopping it (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The rivaroxaban SmPC gives no specific dose for use with inducers (rivaroxaban SmPC, EMA). Routine monitoring of rivaroxaban exposure is not required, but in exceptional situations a calibrated quantitative anti-factor Xa assay can measure it (rivaroxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Fenobarbital (nº registro 3275), sección 4.5 (2025)– AEMPS, CIMA, Luminal 100 mg comprimidos y Luminaletas 15 mg comprimidos (ficha común), nº registro 3275, revisión 07/2025, secciones 4.3 y 4.5